Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Day One Biopharmaceuticals ( (DAWN) ) has issued an update.
On March 2, 2026, Day One Biopharmaceuticals updated its corporate presentation after Ipsen Pharma SAS received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use recommending conditional marketing authorization of OJEMDA as a monotherapy for children with relapsed or refractory BRAF-altered pediatric low-grade glioma. The move underscores Day One’s strategy to build OJEMDA into a global standard of care in pediatric low-grade glioma through its exclusive ex-U.S. licensing deal with Ipsen, while advancing a broader oncology pipeline and signaling a path to sustained revenue growth and strengthened positioning in pediatric oncology therapeutics.
The CHMP’s favorable stance, following Day One’s April 2024 U.S. approval and July 2024 licensing agreement with Ipsen, highlights growing regulatory momentum for OJEMDA in a setting where few approved options exist. For stakeholders, the development points to expanding international commercialization opportunities, reinforces the value of Day One’s pediatric-focused model, and supports the company’s narrative of accelerating growth anchored by OJEMDA and its adjacent oncology programs.
The most recent analyst rating on (DAWN) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on Day One Biopharmaceuticals stock, see the DAWN Stock Forecast page.
Spark’s Take on DAWN Stock
According to Spark, TipRanks’ AI Analyst, DAWN is a Neutral.
The score is driven primarily by improving commercial performance and strong gross margins, plus a low-debt balance sheet, but is held back by persistent net losses and significant negative free cash flow. Technicals are supportive with an established uptrend, and the latest earnings call adds confidence via reiterated 2026 growth guidance, though safety, concentration risk, and gross-to-net pressure remain key watchpoints.
To see Spark’s full report on DAWN stock, click here.
More about Day One Biopharmaceuticals
Day One Biopharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing and delivering targeted, first- or best-in-class therapies for serious childhood and adult diseases, particularly cancers with high unmet medical need. Its lead product, OJEMDA (tovorafenib), received U.S. accelerated approval in April 2024 for pediatric patients with relapsed or refractory low-grade glioma harboring specific BRAF alterations, and the company is pursuing global expansion through partnerships and an oncology-focused pipeline.
Average Trading Volume: 2,589,700
Technical Sentiment Signal: Buy
Current Market Cap: $1.12B
Find detailed analytics on DAWN stock on TipRanks’ Stock Analysis page.